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Variants in the 14q32 miRNA 
cluster are associated with 
osteosarcoma risk in the Spanish 
population
Idoia Martin-Guerrero1, Nerea Bilbao-Aldaiturriaga2, Angela Gutierrez-Camino2, 
Borja Santos-Zorrozua2, Vita Dolžan  3, Ana Patiño-Garcia4 & Africa Garcia-Orad2,5
Association studies in osteosarcoma risk found significant results in intergenic regions, suggesting that 
regions which do not codify for proteins could play an important role. The deregulation of microRNAs 
(miRNAs) has been already associated with osteosarcoma. Consequently, genetic variants affecting 
miRNA function could be associated with risk. This study aimed to evaluate the involvement of all 
genetic variants in pre-miRNAs described so far in relationship to the risk of osteosarcoma. We analyzed 
a total of 213 genetic variants in 206 pre-miRNAs in two cohorts of osteosarcoma patients (n = 100) 
and their corresponding controls (n = 256) from Spanish and Slovenian populations, using Goldengate 
Veracode technology (Illumina). Four polymorphisms in pre-miRNAs at 14q32 miRNA cluster were 
associated with osteosarcoma risk in the Spanish population (rs12894467, rs61992671, rs58834075 and 
rs12879262). Pathway enrichment analysis including target genes of these miRNAs pointed out the 
WNT signaling pathways overrepresented. Moreover, different single nucleotide polymorphism (SNP) 
effects between the two populations included were observed, suggesting the existence of population 
differences. In conclusion, 14q32 miRNA cluster seems to be a hotspot for osteosarcoma susceptibility 
in the Spanish population, but not in the Slovenian, which supports the idea of the existence of 
population differences in developing this disease.
Osteosarcoma is the most common primary malignant bone tumor, mainly occurring in children and adoles-
cents. The precise etiology of the disease remains partially unknown1, but genetic factors seem to play a key role 
in its pathogenesis2,3. To date, several case-control studies have reported associations of common genetic vari-
ants with osteosarcoma risk3–5, but these studies were mainly focused on regions codifying for proteins, because 
results are easily interpreted biologically. However, a genome wide association study (GWAS) in osteosarcoma 
showed that 8 out of the 13 most significant genetic variants were located in regions with no clear functional 
consequence6, results that are more difficult to interpret. Similar results were found in other GWAS in different 
cancer types, in which 44% of significant signals were described to be located in intergenic regions7. All these data 
together suggest that regions which do not codify for proteins could play an important role in the risk of cancer, 
in general, and in osteosarcoma, in particular. One of the most studied non-coding RNAs are microRNAs (miR-
NAs), molecules of 20 nucleotides that regulate gene expression at the post-transcriptional level by binding to the 
3′ untranslated region (UTR) of a target mRNA8, leading to its translation inhibition or degradation. Through this 
mechanism, miRNAs can regulate more than half of human genes9. More than 600 miRNAs have been proposed 
to be involved in osteogenesis regulation10, so it is reasonable to think that miRNAs deregulation can be linked 
to osteosarcoma susceptibility. In fact, alterations of miR-34c affecting Notch signaling pathway were associated 
with the pathogenesis of osteosarcoma11, and the deregulation of the 14q32 miRNA cluster was also linked to the 
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progression and prognosis of osteosarcoma12. Genetic variations in miRNAs can alter their function affecting 
their gene targets. These variants can modify the miRNA expression levels if they are located in the pre-miRNA or 
the mRNA-miRNA binding if they are located in the seed region. Consequently, genetic variations in pre-miRNAs 
affecting their function could be involved in the risk of cancer. Several works have already described polymor-
phisms in miRNAs associated with the susceptibility to different types of cancer13,14. Despite all these evidences, 
few studies have analyzed the involvement of miRNA single nucleotide polymorphism (SNPs) in the risk of 
osteosarcoma so far. Although only a low number of SNPs were analyzed, significant results were found with two 
variations belonging to miR-34 family15,16 and with one located in mir-124a17.
Considering that the number of annotated miRNAs has increased substantially up to 2500 miRNAs approx-
imately18, the aim of this study was to evaluate the contribution in the risk of osteosarcoma of variants in 
pre-miRNAs. With that objective, all variants in pre-miRNAs with a minor allele frequency (MAF) higher than 
1% were analyzed in a representative group of osteosarcoma patients from two populations.
Materials and Methods
Patients. The study population included 100 patients (<34 years) diagnosed of osteosarcoma at the Oncology 
Unit of the Department of Pediatrics of the University Clinic of Navarra (n = 74) between 1985 and 2003 and 
University Children’s Hospital of Liubliana (n = 26) between 1990 and 2008. Both patient cohorts were residents 
in Spain or Slovenia at the moment of diagnosis and had West European ancestry. Moreover, 256 healthy individ-
uals of European origin with no previous history of cancer (n = 160 and n = 96 from Spain and Slovenia, respec-
tively) were added (Table 1). Informed consent was obtained from all patients or their parents before sample 
collection. The study was approved by the Spanish Ethics Committees for Clinical Research of Euskadi (CEIC-E) 
(CEISH/102R/2011/GARCIA-ORAD CARLES 67/02/12) and the University of Navarra (105/2009), and by the 
Slovenian Ethics Committee for Research in Medicine (bilateral project BI- ES/04-05-016) and was carried out 
according to the Declaration of Helsinki.
Selection of polymorphisms in miRNAs. We selected all the pre-miRNAs including SNPs with a 
MAF > 0.01 in European/Caucasian populations described in the databases until May 2014. Since, on the one 
hand, osteosarcoma is a polygenic disease in which associated genes are not totally defined, and, on the other 
hand, a single miRNA can regulate several transcripts which are not completely known nowadays, we decided to 
analyze all polymorphic miRNAs to date. MAF > 0.01 was selected because this frequency was required to detect 
significant differences in our sample size.
The SNP selection was performed using miRNA SNiPer (www.integratomics-time.com/miRNA-SNiPer/), 
NCBI and literature review. Finally, a total of 213 SNPs in 206 pre-miRNAs were included.
Genotyping. Peripheral blood samples were obtained as the source of DNA from Spanish patients and all 
healthy controls, while in Slovenian osteosarcoma patients DNA was extracted from the areas of formalin fixed 
paraffin embedded (FFPE) material verified by an experienced pathologist to be representative of normal tis-
sue. Most FFPE samples were osteogenic (>96%) from histological point of view, and all of them were primary 
malignancy. Genomic DNA was extracted using standard procedures19. DNA was quantified using PicoGreen 
(Invitrogen Corp., Carlsbad, CA). For each sample, 400 ng of DNA were genotyped using the GoldenGate 
Genotyping Assay with Veracode technology according to the published Illumina protocol. Data were ana-
lyzed with Genome Studio software for genotype clustering and calling. As quality control, duplicate samples 
and CEPH trios (Coriell Cell Repository, Camden, NJ) were genotyped across the plates, following the Illumina 
recommendations.
Statistical analysis. The association between genetic polymorphisms and the risk of osteosarcoma was 
evaluated by the χ2 or Fisher’s exact test. The effect sizes of the associations were estimated by the OR’s from 
univariate logistic regression. The most significant test among codominant, dominant, recessive and additive was 
used to determine the statistical significance of each SNP. The results were adjusted for multiple comparisons by 
the False Discovery Rate (FDR)20. In all cases the significance level was set at 5%. Analyses were performed by 
Total Controls Cases
Participants (n) 356 256 100
Population (n;%)
Spain 234 160 (68.37) 74 (31.62)
Slovenia 122 96 (78.68) 26 (21.31)
Age (mean; sd)
Spain 69.01 (17.5) 14.5 (4.7)
Slovenia 46 (9.3) 19.5 (8.6)
Sex (f/m)a
Spain 111/120 81/79 30/41
Slovenia 51/71 35/58 13/13
Table 1. Study population. Abbreviations: n, number of individuals; sd, standard deviation; f, female; m, male. 
aSex was not available for all patients.
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using R v2.11 software. χ2 test was used to search for any deviation of Hardy-Weinberg equilibrium (HWE) in 
controls. Those SNPs that showed deviations from HWE in control population were removed from the analyses.
Bioinformatic analyses. miRNAs secondary structures prediction. The RNAfold web tool (http://rna.tbi.
univie.ac.at) was used to calculate the minimum free energy secondary structures and to predict the most stable 
secondary structures of the miRNAs showing significant SNPs.
miRNAs expression analyses. Expression levels of miRNAs were analyzed in a series of 18 osteosarcoma cell 
lines (<34 years) and 4 normal bone samples, using data publicly available in GEO database under the acces-
sion GSE2842321. T-tests were performed using the GEO2R web tool, applying a Benjamini and Hochberg FDR 
adjusted p-value cut-off of 0.05.
Gene targets selection and pathways analysis. MiRWalk22 (http://zmf.umm.uni-heidelberg.de/apps/zmf/miR-
walk2/) database was used to select miRNA targets. Only targets predicted by at least 8 different algorithms 
provided by miRWalk were selected. Enriched pathway analyses of putative target genes were determined with 
ConsensusPath database (CPdB) (http://consensuspathdb.org/)23 using the over-representation analysis module. 
Gene list were analyzed against the default collection of KEGG24, Reactome25 and BioCarta (http://cgap.nci.nih.
gov/Pathways/BioCarta_Pathways) pathway databases. A conservative p-value cutoff (0.001) was used.
Results
Genotyping results. Genotyping analyses were performed in 100 patients diagnosed of osteosarcoma (74 
Spanish and 26 Slovenian) and 256 cancer-free controls (160 and 96, respectively). Successful genotyping was 
obtained in 350 of 356 DNA samples (98.3%). Finally, a total of 140 SNPs were included in the association anal-
yses, after eliminating SNPs with genotyping failures (<80%), monomorphic in the studied populations, or with 
deviations from HWE in controls (Table S1).
Genotype association study. We found 23 SNPs significantly associated with osteosarcoma risk; 14 SNPs 
in 14 miRNAs in the Spanish population and 9 SNPs in 8 miRNAs in the Slovenian. When the two populations 
were analyzed together, 11 SNPs at 11 miRNAs were significant.
In the Spanish population, 4 out of 14 significant SNPs were located at 14q32 region (Fig. 1). Among them, 
rs12894467 at miR-300 showed the most significant association value under the log-additive model (CC vs CT vs 
TT). The frequency of TT genotype was found to be 2.5 times higher in patients than in controls (OR = 2.01, 95% 
CI: 1.32–3.06; P = 0.001). With regard to the other three significant SNPs at 14q32 region, we found an increase in 
the risk of osteosarcoma for the genotypes AG + AA for rs61992671, CT for rs58834075 and CG for rs12879262 
located at miR-412, miR-656 and miR-4309, respectively (OR = 2.21, OR = 4.98 and OR = 1.99). Other 10 SNPs 
showed statistically significant results (P < 0.05), 6 located in pre-miRNAs, 2 in mature miRNAs and 1 in the seed 
region (Table 2). After FDR correction, no SNP remained significant.
Figure 1. 14q32 miRNA cluster. (A) Diagram of the 14q32 miRNA cluster, including miRNAs analyzed in 
our study (in bold), miRNAs with significant SNPs (highlighted with an asterisk), and miRNAs described in 
the literature to be downregulated. (B) Secondary structures of the 14q32 miRNAs showing significant SNPs, 
predicted by RNAfold web tool.
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In the Slovenian population, 9 SNPs were significant. Among them, rs35613341 at miR-5189 showed the 
most significant association. The genotype CG for rs35613341 showed a protective effect (OR = 0.07, 95% CI: 
0.01–0.59; under codominant model), association that remained significant after FDR correction. Another geno-
type in the same miRNA (AG + AA for rs56292801) also showed protective effect (OR = 0.25; 95% CI:0.08–0.80). 
Other 7 SNPs displayed significant results (P < 0.05), 4 located in pre-miRNAs and 3 in the seed region (Table 3).
None of the miRNAs significant in the Spanish population were significant in the Slovenian.
In the global analysis, a total of 11 significant SNPs were detected. Nine of them had been already found sig-
nificant in the Spanish or in the Slovenian populations. Among them, 3 SNPs showed more significant and 5 less 
significant P values in the total population than those found in each population separately. The other 3 out of 11 
significant associations detected were new (Table S2). From the total of significant SNPs observed in the Spanish 
SNP miRNA Localization Genotype
N (%)controls 
N = 160
N (%)cases 
N = 69 OR (CI 95%) P
1 rs12894467 mir-300 14q32pre-miRNA
CC 74 (46.2) 19 (27.5)
2.01 (1.32–3.06) 0.001 (add)CT 71 (44.4) 34 (49.3)
TT 15 (9.4) 16 (23.2)
2 rs356125 mir-2278 9q22pre-miRNA
GG 140 (87.5) 68 (98.6) 1
0.002 (codom)AG 20 (12.5) 1 (1.4) 0.1 (0.01–0.78)
AA 0 (0 0 (0) 0.00 (0.00)
3 rs77639117 mir-576 4q25pre-miRNA
AA 156 (97.5) 60 (87.0) 1
0.003 (codom)AT 4 (2.5) 9 (13.0) 5.85 (1.74–19.71)
TT 0 (0) 0 (0) 0.00 (0.00)
4 rs7247237 mir-3188 19p13pre-miRNA
CC 72 (45.3) 23 (34.3) 1
0.004 (rec)CT 77 (48.4) 31 (46.3) 3.59 (1.49–8.66)
TT 10 (6.3) 13 (19.4)
5 rs60871950 mir-4467 7q22.1miRNA
GG 35 (22.0) 27 (39.1) 1
0.009 (dom)AG 83 (52.2) 23 (33.3) 0.44 (0.24–0.81)
AA 41 (25.8) 19 (27.5)
6 rs10505168 mir-2053 8q23.3pre-miRNA
AA 78 (49.1) 25 (36.2) 1
0.009 (codom)AG 65 (40.9) 42 (60.9) 2.02 (1.11–3.65)
GG 16 (10.1) 2 (2.9) 0.39 (0.08–1.81)
7 rs61992671 mir-412 14q32miRNA
GG 57 (35.6) 13 (20.0) 1
0.018 (dom)AG 66 (41.2) 35 (53.8) 2.21 (1.11–4.41)
AA 37 (23.1) 17 (26.2)
8 rs58834075 mir-656 14q32pre-miRNA
CC 157 (98.1) 63 (91.3) 1
0.021 (codom)CT 3 (1.9) 6 (8.7) 4.98 (1.21–20.55)
TT 0 (0) 0 (0)
9 rs10406069 mir-5196 19q13pre-miRNA
GG 110 (69.6) 43 (62.3) 1
0.021 (codom)AG 39 (24.7) 26 (37.7) 1.71 (0.93–3.13)
AA 9 (5.7) 0 (0.0) 0.00 (0.00)
10 rs12879262 mir-4309 14q32pre-miRNA
GG 111 (69.8) 39 (56.5) 1
0.022 (codom)CG 43 (27.0) 30 (43.5) 1.99 (1.10–3.59)
CC 5 (3.1) 0 (0.0) 0.00 (0.00)
11 rs702742 mir-378h 5q33pre-miRNA
AA 117 (73.1) 58 (86.6) 1
0.022 (dom)AG 41 (25.6) 8 (11.9) 0.42 (0.19–0.93)
GG 2 (1.2) 1 (1.5)
12 rs10422347 mir-4745 19p13miRNA
CC 138 (87.3) 51 (75.0) 1
0.025 (dom)CT 19 (12.0) 17 (25.0) 2.30 (1.12–4.73)
TT 1 (0.6) 0 (0.0)
13 rs2289030 mir-492 12q22pre-miRNA
CC 130 (81.2) 60 (87.0) 1
0.026 (rec)CG 30 (18.8) 6 (8.7) 0.00
GG 0 (0.0) 3 (4.3)
14 rs35770269 mir-449c 5q11seed
AA 61 (38.4) 35 (50.7)
0.64 (0.42–0.98) 0.038 (add)AT 71 (44.7) 28 (40.6)
TT 27 (17.0) 6 (8.7)
Table 2. Polymorphisms in miRNAs associated with osteosarcoma risk in the Spanish population. 
Abbreviations: OR, Odd Ratio; CI, Confidence Interval; add, additive; codom, codominant; dom, dominant; 
rec, recessive.
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(n = 14) or in the Slovenian population (n = 9), 14 did not show significant results when both population were 
analyzed together.
miRNAs secondary structures. We analyzed in silico the energy change (|ΔΔG|) and the secondary struc-
tures of the miRNAs with significant SNPs. In the Spanish population, 4/14 miRNAs showed drastic energy 
changes (>2.0 Kcal/mol) and 7 showed altered secondary structure (Fig. S1). With regard to the SNPs at 14q32 
region, rs61992671 in miR-412 and rs58834075 in miR-656 induced positive energy changes which turned the 
miRNA hairpins from a stable to an unstable status. In the Slovenian population, 2/9 miRNAs showed energy 
changes >2.0 Kcal/mol and 3 displayed secondary structure changes (Fig. S2). In the global analysis, 2 of the 3 
new detected miRNAs showed energy changes >2.0 Kcal/mol and all of them showed changes in the secondary 
structure (Fig. S3).
miRNA expression. We studied the expression levels of miRNAs of interest in osteosarcoma cell lines using 
the public database Gene Expression Omnibus (GEO). Out of 22 miRNAs with significant SNPs, 5 miRNAs were 
represented in the GSE28423 database (miR-300, miR-412, miR-492, miR-576 and miR-656). From them, mir-
300 was found significantly down-regulated in osteosarcoma cell lines group (logFC = −1.545; adj-p = 0.006). 
The rest of miRNAs showed no significant results (p > 0.05).
Pathway analysis. We performed a pathway enrichment analysis with miRNAs of 14q32 region that mod-
ified the secondary structure, miR-412 and miR-656, using miRWalk database and ConsensusPathDB web tool. 
MiR-300 (the most significant SNP) was also included in pathway enrichment analysis although no remark-
able results were observed (data not shown). For miR-412, we found two pathways over-represented, being 
both WNT signaling predicted by KEGG and Biocarta (Table S3). Regarding miR-656, only Ca2+ pathway was 
over-represented, with 7/55 genes targeted by this miRNA (Table S4). Of these 7 genes, 5 overlapped with WNT 
signaling pathway. When both miRNAs were analyzed together, 5 pathways were over-represented, being WNT 
signaling pathway the most significant (p = 0.000177) (Table S5), with 16/143 genes targeted by miR-412 and 
miR-656 (Table S6).
N SNP miRNA Localization Genotype
N (%) controls 
N = 96
N(%) cases 
N = 25 OR (CI 95%) P
1 rs35613341 mir-5189 16q24 pre-miRNA
CC 49 (51.0) 16 (69.6) 1
0.0001* (codom)CG 41 (42.7) 1 (4.3) 0.07 (0.01–0.59)
GG 6 (6.2) 6 (26.1) 3.06 (0.86–10.85)
2 rs4674470 mir-4268 2q35 pre-miRNA
TT 50 (52.1) 17 (85.0) 1
0.002 (codom)CT 40 (41.7) 1 (5.0) 0.07 (0.01 0.58)
CC 6 (6.2) 2 (10.0) 0.98 (0.18 5.33)
3 rs2070960 mir-3620 1q42 seed
CC 75 (78.9) 21 (87.5) 1
0.008 (codom)CT 20 (21.1) 1 (4.2) 0.18 (0.02–1.41)
TT 0 (0.0) 2 (8.3) 0
4 rs56292801 mir-5189 16q24 pre-miRNA
GG 51 (53.1) 18 (81.8) 1
0.010 (dom)AG 41 (42.7) 3 (13.6) 0.25 (0.08–0.80)
AA 4 (4.2) 1 (4.5)
5 rs2273626 mir-4707 14q11 seed
AA 31 (32.3) 2 (8.7) 1
0.013 (dom)AC 45 (46.9) 15 (65.2) 5.01 (1.10–22.72)
CC 20 (20.8) 6 (26.1)
6 rs6726779 mir-4431 2p16 pre-miRNA
TT 34 (35.8) 12 (63.2) 1
0.027 (codom)CT 51 (53.7) 4 (21.1) 0.22 (0.07–0.75)
CC 10 (10.5) 3 (15.8) 0.85 (0.20–3.62)
7 rs9877402 mir-5680 8q22 pre-miRNA
AA 88 (93.6) 17 (85.0) 1
0.030 (rec)AG 6 (6.4) 1 (5.0) 0
GG 0 (0.0) 2 (10.0)
8 rs243080 mir-4432 2p16 pre-miRNA
CC 30 (31.6) 12 (57.1) 1
0.030 (dom)CT 49 (51.6) 5 (23.8) 0.35 (0.13–0.91)
TT 16 (16.8) 4 (19.0)
9 rs3746444 mir-499a 20q11 seed
TT 64 (66.7) 18 (75.0) 1
0.044 (rec)CT 30 (31.2) 3 (12.5) 6.71 (1.06–42.73)
CC 2 (2.1) 3 (12.5)
Table 3. Polymorphisms in miRNAs associated with osteosarcoma risk in the Slovenian population. 
*Significant after FDR correction. Abbreviations: OR, Odd Ratio; CI, Confidence Interval; add, additive; 
codom, codominant; dom, dominant; rec, recessive.
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Discussion
In the Spanish population, the most interesting result was that 4 genetic variants in miRNAs belonging to the 
14q32 miRNA cluster were statistically associated with the risk of osteosarcoma. From these, rs12894467 T allele 
at miR-300 showed the most significant result, conferring a 2.01-fold increased risk. This polymorphism was also 
found significant when Spanish and Slovenian populations were analyzed together, what means that it showed 
the same trend in both cohorts (although it was not significant in the Slovenian sample individually). The other 
3 significant SNPs of the cluster in the Spanish population (rs61992671, rs58834075 and rs12879262 at miR-412, 
miR-656 and miR-4309, respectively) were also associated with an increased risk of osteosarcoma. Interestingly, 
miRNAs of this cluster were found to be under-expressed in osteosarcoma in previous studies26,27. This miRNAs 
downregulation was correlated with MYC overexpression, that it is known to be related to the development of 
osteosarcoma27. The miRNAs down-expression was confirmed for mir-300 in a series of osteosarcoma cell lines 
using GEO dataset GSE28423. Moreover, the block of 14q32 miRNAs was shown to increase the tumorigenic 
potential in osteoblasts, suggesting that they could work as tumor suppressors. Consequently, the loss of function 
of these miRNAs could be considered as a causative factor in osteosarcomagenesis27. Supporting this idea, the bio-
informatical analysis predicted that the SNPs in miR-412 and miR-656 decreased the stability of the miRNA hair-
pins, which has been suggested that may reduce the product of the mature miRNA28. This reduction in miRNA 
levels could increase the expression of their target genes. Interestingly, pathway analyses pointed out the WNT 
pathway as the most over-represented pathway, which is known to play an important role in osteoblastogenesis29. 
Other authors have also pointed out the involvement of WNT pathway in the development of osteosarcoma30,31. 
Dysregulation of Wnt signaling pathway allows β-catenin to accumulate and translocate into the nucleus, where 
it activates downstream oncogenes including MYC32. Considering these previous studies, we can hypothesize 
that variations in the pre-miRNAs miR-300, miR-412, miR-656 or miR-4309 could lead to their downregulation, 
altering the Wnt pathway which ultimately would lead to the overexpression of MYC. All these results would 
support the hypothesis that this region is a hotspot for the development of osteosarcoma. In fact, recent studies in 
early-onset osteosarcoma have shown that inherited imprinting defects in14q32 region affects gene and miRNA 
expression in this area, which could be associated with the pathobiology of osteosarcoma33.
Another interesting result in the Spanish population was found for rs35770269, located in the seed region 
of miR-449c. In this case, the T allele was observed to decrease the risk of osteosarcoma (OR = 0.64). This allele 
was proposed to alter the secondary structure of the miRNA (in silico), so the T allele could have a double action 
in the miRNA, one affecting its levels and another, the miRNA-mRNA binding. Of note, miR-449c is part of the 
highly conserved miR-449 cluster belonging to the miR-34 family34, a key regulator of tumor suppression35. SNPs 
in the miR-34 family had already been found involved in the risk of osteosarcoma: rs4938723 C and rs72631823 
A were associated with a reduction of miR-34b and miR-34a, respectively15,16. In addition, the underexpression 
of miR-34a was shown to downregulate the suppression of the proto-oncogene C-MET, promoting osteosarcoma 
cell proliferation and migration16. Since miRNAs belonging to the same family usually share target genes, we can 
hypothesize that rs35770269 could affect the binding of miR-449c to MET.
The other 9 significant miRNA variants detected in the Spanish population also showed a putative effect on 
target genes with known involvement in osteosarcoma. For instance, rs77639117 T allele could increase the risk 
of osteosarcoma through upregulating miR-576, which in turn might downregulate RB1, a tumor suppressor gene 
inactivated in 35% of osteosarcoma patients1. The genotype rs2289030 GG could alter miR-492, affecting its target 
PTEN. This gene was previously shown to be downregulated in osteosarcoma cells36–38. Rs6087195 could alter 
the expression levels of miR-4467, which consequently could alter the expression of its putative target gene SF1, 
involved in DNA reparation function39. In this case, the miRNA dysfunction could be explained by a modification 
of the pre-miRNA secondary structure and a drastic energy change (3.9 Kcal/mol), which has been suggested to 
affect the stability of the miRNA28.
In the Slovenian population, rs35613341 and rs56292801 (both located at miR-5189) showed the most 
remarkable results. In this case, the significant association was caused by a decrease of the percentage of hete-
rozygotes and an increase of the percentage of homozygotes. This fact suggests the presence of a deletion in this 
region in which a copy number variation (CNV) (according to the database of Genomic Variations) has been 
described. To the best of our knowledge, this is the first time that this CNV is associated with osteosarcoma 
risk. Another interesting finding was observed for rs3746444 located in the seed region of the pre-miR-499. The 
GG genotype was associated with increased risk of osteosarcoma. Similar results were observed in two previous 
meta-analyses studying the involvement of this polymorphism in cancer susceptibility in Caucasians (although 
not significant)40,41.
When both populations were analyzed together, a total of 6 SNPs increased the significance of association 
with respect to the individual analyses. These results indicate that all these SNPs showed the same trend in both 
populations, so they could be considered as disease markers. Among them, rs2910164 at miR-146a was previously 
associated with diverse types of cancer42,43. This SNP was also analyzed in relation to the risk of osteosarcoma 
in Chinese, showing the same trend as in our population (but it was not significant)16. When a meta-analysis 
including the three populations (Chinese, Spanish and Slovenian) was performed, a significant association was 
found under the dominant model (P = 0.003). The CG + CC rs2910164 genotype showed an OR = 0.57 (95% CI: 
0.39–0.83) (Fig. S4). However, 5 SNPs decreased their significance level, what means that opposite results were 
detected in the two populations. This suggests that these SNPs are population specific, which indicates remarkable 
population differences in factors contributing to osteosarcoma risk.
This study has some limitations that might be addressed, such as the limited sample size. Nevertheless, consid-
ering the scarcity of the disease, we think that the number of patients included in the present study was enough 
to obtain valid results. Another possible weakness of the study was the relatively high failure rate in genotyping 
technique. However, this high chance of failure was accepted from the beginning, because despite the predicted 
problem with the technique, no other design option to amplify these polymorphisms was possible.
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In conclusion, the most important findings of the present study indicated that SNPs located at the 14q32 
miRNA cluster can be involved in the susceptibility of osteosarcoma in the Spanish population, confirming the 
interest of this region in the disease. Our results also confirm the existence of population differences in the risk of 
developing osteosarcoma. To our knowledge, this is the first study analyzing in depth so many SNPs at miRNAs 
in relation with the risk of osteosarcoma, which opens a promising approach to search for new susceptibility 
markers in this disease. New large-scale studies including functional analyses will help to validate our findings.
Ethics approval and consent to participate. All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of the institutional and/or national research committee 
and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
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